The DOI matches its Crossref record; 237 of the 237 references it cites were found in a registry or an index.
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Open accessAbstract
Chimeric antigen receptor (CAR) T cell therapies have demonstrated remarkable efficacy for the treatment of hematological malignancies. However, in patients with solid tumors, objective responses to CAR-T cell therapy remain sporadic and transient. A major obstacle for CAR-T cells is the intrinsic ability of tumors to evade immune responses. Advanced solid tumors are largely composed of desmoplastic stroma and immunosuppressive modulators, and characterized by aberrant cell proliferation and vascularization, resulting in hypoxia and altered nutrient availability. To mount a curative response after infusion, CAR-T cells must infiltrate the tumor, recognize their cognate antigen and perform their effector function in this hostile tumor microenvironment, to then differentiate and persist as memory T cells that confer long-term protection. Fortunately, recent advances in synthetic biology provide a wide set of tools to genetically modify CAR-T cells to overcome some of these obstacles. In this review, we provide a comprehensive overview of the key tumor intrinsic mechanisms that prevent an effective CAR-T cell antitumor response and we discuss the most promising strategies to prevent tumor escape to CAR-T cell therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–237 of 237
Zhang, Y., & Ertl, H. C. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7818 · Cited by 108
Lee, J., Hayman, E. G., Pegram, H. J., Santos, E. B., Heller, G., Sadelain, M., & Brentjens, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0552 · Cited by 106
Xie, Y. J., Dougan, M. L., Ingram, J. R., Pishesha, N., Fang, T., Momin, N., & Ploegh, H. L. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0734 · Cited by 105
Li, H., Ding, J., Lü, M., Liu, H., Miao, Y., Li, L., Wang, G., Zheng, J., Pei, D., & Zhang, Q. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000301 · Cited by 103
Santoro, S. P., Kim, S., Motz, G. T., Alatzoglou, D., Li, C., Irving, M. B., Powell, D. J., & Coukos, G. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0192 · Cited by 102
Self-citationPlasticity beyond Cancer Cells and the “Immunosuppressive Switch”
Granot, Z., & Fridlender, Z. G. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1502 · Cited by 102
Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Teijeira, Á., Labiano, S., Garasa, S., Etxeberría, I., Santamaría, E., Rouzaut, A., Enamorado, M., Azpilikueta, A., Inogés, S., Bolaños, E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0767 · Cited by 101
Petrausch, U., Schuberth, P., Hagedorn, C., Soltermann, A., Tomaszek, S. C., Stahel, R. A., Weder, W., & Renner, C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-615 · Cited by 100
Hypoxia Selectively Impairs CAR-T Cells In Vitro
Berahovich, R., Liu, X., Zhou, H., Tsadik, E., Xu, S., Golubovskaya, V., & Wu, L. (2019) · Cancers · doi:10.3390/cancers11050602 · Cited by 100
Perera, L. P., Zhang, M., Nakagawa, M., Petrus, M. N., Maeda, M., Kadin, M. E., Waldmann, T. A., & Perera, P. (2017) · American Journal of Hematology · doi:10.1002/ajh.24794 · Cited by 99
Wang, W., Ma, Y., Li, J., Shi, H., Lq, W., Guo, F.-C., Zhang, J., Li, D., Mo, B.-H., Wen, F., et al. (2013) · Gene Therapy · doi:10.1038/gt.2013.19 · Cited by 97
Golumba-Nagy, V., Kuehle, J., Hombach, A. A., & Abken, H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.005 · Cited by 96
Koehler, H., Kofler, D. M., Hombach, A. A., & Abken, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2098 · Cited by 95
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
Parisi, G., Saco, J. D., Salazar, F. B., Tsoi, J., Krystofinski, P. E., Puig-Saus, C., Zhang, R., Zhou, J., Cheung-Lau, G. C., Garcia, A. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-12901-3 · Cited by 94
Adusumilli, P. S., Zauderer, M. G., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Ngai, D. A., McGee, E., Chintala, N. K., Messinger, J., Cheema, W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2511 · Cited by 93
Liao, Y., Ni, Y., Ren, H., Liu, W., & Du, J. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1471-8 · Cited by 92
Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells
Di, S., Zhou, M., Pan, Z., Sun, R., Chen, M., Jiang, H., Shi, B., Luo, H., & Li, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00241 · Cited by 92
Blair, A. B., Kim, V. M., Muth, S. T., Saung, M. T., Lokker, N. A., Blouw, B., Armstrong, T. D., Jaffee, E. M., Tsujikawa, T., Coussens, L. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4192 · Cited by 90
Menger, L., Śledzińska, A., Bergerhoff, K. F., Vargas, F. A., Smith, J. N. P., Poirot, L., Pulè, M. A., Herrero, J., Peggs, K. S., & Quezada, S. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3352 · Cited by 82
Clift, R., Souratha, J., Garrovillo, S. A., Zimmerman, S. J., & Blouw, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3060 · Cited by 79
Analysis of CAR-Mediated Tonic Signaling
Calderón, H., Mamonkin, M., & Guedan, S. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0146-4_17 · Cited by 76
Self-citationSuryadevara, C. M., Desai, R. R., Farber, S. H., Choi, B. D., Swartz, A. M., Shen, S. H., Gedeon, P. C., Snyder, D. J., Herndon, J. E., Healy, P. N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1211 · Cited by 75
Thoreau, M., Penny, H. L., Tan, K. W., Régnier, F., Weiss, J. M., Lee, B. T. K., Johannes, L., Dransart, E., Bon, A. L., Abastado, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4940 · Cited by 74
Mardiana, S., John, L. B., Henderson, M. A., Slaney, C. Y., von Scheidt, B., Giuffrida, L., Davenport, A. J., Trapani, J. A., Neeson, P. J., Loi, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1831 · Cited by 74
Gulati, P., Rühl, J., Kannan, A., Pircher, M., Schuberth, P., Nytko, K. J., Pruschy, M. N., Sulser, S., Haefner, M., Jensen, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1788 · Cited by 73
Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma
Cui, J., Zhang, Q., Song, Q., Wang, H., Dmitriev, P., Sun, M., Cao, X., Wang, Y., Guo, L., Indig, I. H., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz117 · Cited by 71
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy
Smith, J. B., Lanitis, E., Dangaj, D., Buza, E., Poussin, M., Stashwick, C., Scholler, N., & Powell, D. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.149 · Cited by 58 · cited 1×
“Similarly, CAR-T cell targeting B7-H4, a molecule expressed by cancer cells and TAMs, mediated antitumor responses in a preclinical ovarian cancermodel, but was also toxic due to possible targeting of tissue resident macrophages (57).”
BackgroundLi, H., Zheng, J., Fan, H., Li, H., Gao, Z., & Chen, D. (2013) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12044 · Cited by 58
Hornig, N., Kermer, V., Frey, K., Diebolder, P., Kontermann, R. E., & Müller, D. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182594387 · Cited by 48
Kawashima, M., Carreras, J., Higuchi, H., Kotaki, R., Hoshina, T., Okuyama, K., Suzuki, N., Kakizaki, M., Miyatake, Y., Ando, K., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0737-9 · Cited by 46
Calvino, A. S., Licata, L. A., Burga, R. A., Thorn, M., McCormack, E. M., Stainken, B. F., Assanah, E. O., Khare, P. D., Davies, R., Espat, N. J., et al. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.50 · Cited by 39
Li, N., Luo, H., Liu, X., Ma, S., He, L., Chen, R., Fang, H., & Zhang, D. (2015) · Oncotarget · doi:10.18632/oncotarget.6627 · Cited by 35
Enterotoxins can support CAR T cells against solid tumors
von Scheidt, B., Wang, M., Oliver, A. J., Chan, J. D., Jana, M. K., Ali, A. I., Clow, F., Fraser, J. D., Quinn, K. M., Darcy, P. K., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904618116 · Cited by 32
Shameli, A., Yamanouchi, J., Tsai, S. J., Yang, Y., Clemente‐Casares, X., Moore, A. V., Serra, P., & Santamaría, P. (2012) · European Journal of Immunology · doi:10.1002/eji.201242845 · Cited by 30
Kegler, A., Koristka, S., Bergmann, R., Berndt, N., Arndt, C., Feldmann, A., Hoffmann, A., Bornhäuser, M., Schmitz, M., & Bachmann, M. P. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1621676 · Cited by 25
Heslop, H. E., & Brenner, M. K. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.004 · Cited by 18
Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity
Smith, M. M., Littmann, E. R., Slingerland, J. B., Clurman, A. G., Slingerland, A. E., Taur, Y., Schlüter, J., Park, J. H., O'Cearbhaill, R. E., Mailankody, S., et al. (2018) · Blood · doi:10.1182/blood-2018-99-118628 · Cited by 17
Cited by
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Baulu, E., Gardet, C., Chuvin, N., & Depil, S. (2023) · Science Advances · doi:10.1126/sciadv.adf3700 · Cited by 429
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
Gumber, D., & Wang, L. D. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103941 · Cited by 396
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
Metadata
- Authors
- Rodriguez-Garcia, A., Palazon, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-06-17
- Volume
- 11
- Pages
- 1109-1109
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3036012880
- Cited by
- 312
- References
- 237
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.